207 related items for PubMed ID: 11140430
1. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers.
Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT.
Clin Pharmacokinet; 2000; 39 Suppl 1():23-30. PubMed ID: 11140430
[Abstract] [Full Text] [Related]
2. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma.
Falcoz C, Horton J, Mackie AE, Harding SM, Daley-Yates PT.
Clin Pharmacokinet; 2000; 39 Suppl 1():31-7. PubMed ID: 11140431
[Abstract] [Full Text] [Related]
3. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
Möllmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, Daley-Yates PT, Krieg M, Stöckmann R, Barth J, Lawlor C, Möllmann AC, Derendorf H, Hochhaus G.
J Clin Pharmacol; 2001 Dec; 41(12):1329-38. PubMed ID: 11762560
[Abstract] [Full Text] [Related]
4. Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers.
Brindley C, Falcoz C, Mackie AE, Bye A.
Clin Pharmacokinet; 2000 Dec; 39 Suppl 1():1-8. PubMed ID: 11140428
[Abstract] [Full Text] [Related]
5. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Galant SP, van Bavel J, Finn A, Gross G, Pleskow W, Brown A, Hamedani AG, Harding SM.
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
[Abstract] [Full Text] [Related]
6.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
7. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT.
Clin Pharmacokinet; 2000 Mar; 39 Suppl 1():17-22. PubMed ID: 11140429
[Abstract] [Full Text] [Related]
8. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.
Mackie AE, Bye A.
Clin Pharmacokinet; 2000 Mar; 39 Suppl 1():47-54. PubMed ID: 11140433
[Abstract] [Full Text] [Related]
9. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
Bateman ED, Silins V, Bogolubov M.
Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
[Abstract] [Full Text] [Related]
10. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT, Deans A, Mehta R, Sousa AR.
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[Abstract] [Full Text] [Related]
11.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R, Daley-Yates PT, Jenkins K, Bianco J, Stylianou A, Louey MD, Chan RH.
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[Abstract] [Full Text] [Related]
13. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.
Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A.
Lancet; 2000 Aug 12; 356(9229):556-61. PubMed ID: 10950233
[Abstract] [Full Text] [Related]
14. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma.
Daley-Yates PT, Tournant J, Kunka RL.
Clin Pharmacokinet; 2000 Aug 12; 39 Suppl 1():39-45. PubMed ID: 11140432
[Abstract] [Full Text] [Related]
15.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
16. A study on the clinical equivalence and patient preference of fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients.
Pieters WR, Stallaert RA, Prins J, Greefhorst AP, Bosman HG, van Uffelen R, Schreurs AJ, van Helmond JL, Janssen PG.
J Asthma; 1998 Aug 12; 35(4):337-45. PubMed ID: 9669827
[Abstract] [Full Text] [Related]
17. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN.
Ann Allergy Asthma Immunol; 2001 Apr 12; 86(4):397-404. PubMed ID: 11345282
[Abstract] [Full Text] [Related]
18.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
19. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ.
Br J Clin Pharmacol; 2001 Jul 12; 52(1):93-5. PubMed ID: 11453895
[Abstract] [Full Text] [Related]
20. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers.
Dempsey OJ, Humphreys M, Coutie WJ, Lipworth BJ.
Eur J Clin Pharmacol; 2001 Nov 12; 57(9):637-41. PubMed ID: 11791892
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
